LEXICON PHARMACEUTICALS, INC. Deferred Tax Assets, Valuation Allowance
LEXICON PHARMACEUTICALS, INC. (LXRX) had Deferred Tax Assets, Valuation Allowance of $431.04 million as of 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance
us-gaap:DeferredTaxAssetsValuationAllowance · last filed 2026-03-05
- 2025-12-31: Deferred Tax Assets, Valuation Allowance $431.04M.
- 2024-12-31: Deferred Tax Assets, Valuation Allowance $420.93M.
- 2023-12-31: Deferred Tax Assets, Valuation Allowance $390.17M.
- 2022-12-31: Deferred Tax Assets, Valuation Allowance $345.76M.
| Period end | Deferred Tax Assets, Valuation Allowance | Deferred Tax Assets, Valuation Allowance as first filed |
|---|---|---|
| 2025-12-31 | $431.04M 10-K · filed 2026-03-05 | |
| 2024-12-31 | $420.93M 10-K · filed 2026-03-05 | |
| 2023-12-31 | $390.17M 10-K · filed 2025-03-07 | |
| 2022-12-31 | $345.76M 10-K · filed 2024-03-25 | |
| 2021-12-31 | $326.22M 10-K · filed 2023-03-03 | |
| 2020-12-31 | $309.01M 10-K · filed 2022-03-10 | |
| 2019-12-31 | $329.43M 10-K · filed 2021-03-12 | |
| 2018-12-31 | $364.70M 10-K · filed 2020-03-12 | |
| 2017-12-31 | $341.76M 10-K · filed 2019-03-15 | $347.30M 10-K · filed 2018-03-01 |
| 2016-12-31 | $468.39M 10-K · filed 2018-03-01 | -$468.39M 10-K · filed 2017-03-06 |
| 2015-12-31 | -$413.61M 10-K · filed 2017-03-06 | |
| 2014-12-31 | -$412.42M 10-K · filed 2016-03-11 | |
| 2013-12-31 | -$376.61M 10-K · filed 2015-03-12 | |
| 2012-12-31 | -$348.45M 10-K · filed 2014-03-07 | |
| 2011-12-31 | -$314.99M 10-K · filed 2013-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |